CVM CEL SCI CORP

NYSE cel-sci.com


$ 9.30 $ 0.15 (1.65 %)    

Tuesday, 21-Oct-2025 14:21:22 EDT
QQQ $ 611.71 $ 0.18 (0.03 %)
DIA $ 469.61 $ 2.48 (0.53 %)
SPY $ 671.72 $ 0.24 (0.04 %)
TLT $ 91.95 $ -0.04 (-0.04 %)
GLD $ 379.13 $ -7.51 (-1.94 %)
$ 9.14
$ 8.95
$ 9.01 x 20
$ 9.15 x 36
$ 8.85 - $ 9.32
$ 1.98 - $ 32.70
42,958
na
62.9M
$ 1.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-Q
4 01-13-2025 09-30-2024 10-K
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 02-14-2024 12-31-2023 10-Q
8 12-21-2023 09-30-2023 10-K
9 08-10-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 02-14-2023 12-31-2022 10-Q
12 12-27-2022 09-30-2022 10-K
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 02-11-2022 12-31-2021 10-Q
16 12-21-2021 09-30-2021 10-K
17 08-13-2021 06-30-2021 10-Q
18 05-17-2021 03-31-2021 10-Q
19 02-12-2021 12-31-2020 10-Q
20 12-29-2020 09-30-2020 10-K
21 08-10-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 02-10-2020 12-31-2019 10-Q
24 12-16-2019 09-30-2019 10-K
25 08-14-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 02-14-2019 12-31-2018 10-Q
28 12-19-2018 09-30-2018 10-K
29 08-14-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 02-12-2018 12-31-2017 10-Q
32 12-29-2017 09-30-2017 10-K
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 02-09-2017 12-31-2016 10-Q
36 12-14-2016 09-30-2016 10-K
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 02-09-2016 12-31-2015 10-Q
40 12-11-2015 09-30-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stock-market-today-nvidia-drags-down-nasdaq-futures-dow-trades-higherdollar-general-dell-best-buy-in-focus-updated

U.S. stock futures were swinging on Thursday following Wednesday's advances. Futures of major benchmark indices were largel...

 why-is-cel-sci-stock-crashing-after-hours

CEL-SCI's shares dropped 38.19% after announcing a $10 million public offering priced below market value to fund its cancer...

 cel-sci-announces-proposed-public-offering-no-size-or-amount-disclosed

CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company,toda...

 cel-sci-q3-eps-136-up-from-418-yoy

CEL-SCI (AMEX:CVM) reported quarterly losses of $(1.36) per share. This is a 67.46 percent increase over losses of $(4.18) per ...

 cel-sci-signs-mou-with-leading-saudi-pharma-breakthrough-medicine-designation-filed-for-multikine-with-sfda-eyes-mena-expansion

Memorandum of Understanding (MOU) signed with a leading Saudi Arabian pharma company which submitted the Breakthrough Medicine ...

Core News & Articles

https://www.businessinsider.com/short-squeeze-stock-market-meme-stocks-retail-investors-25-8

 cel-sci-announces-57m-best-efforts-offering-of-15m-shares-at-382share-to-fund-cancer-immunotherapy-development

CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, tod...

 cel-sci-signs-partnership-agreement-with-saudi-arabian-pharma-and-healthcare-company-on-regulatory-and-commercial-activities-for-multikine-in-kingdom-of-saudia-arabia

Strong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East...

Core News & Articles

FDA priority review and approval based on interim results sets a positive precedent, paving the path for future Multikine appro...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION